To evaluate which Bcl-2 family members are critically affected by AZD6244 treatment, we determined their protein levels in the three sensitive lung cancer cell lines after treatment with 3 μM AZD6244, the concentration reached in the serum of patients receiving oral AZD6244. This evidence concerns the gene BCL2 and lung carcinoma.